Clinical Trial Update: Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. [Phase 1]

View source ↗

Summary

This Phase 1 study is evaluating the safety and efficacy of TX103 CAR-T cell therapy in patients with recurrent or progressive Grade 4 glioma (high-grade glioma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• TX103 CAR-T Cell Therapy

Snippet

Sponsor: Tcelltech Inc. | Conditions: High-grade Glioma, WHO Grade Ⅳ Glioma | Phase 1 | Status: RECRUITING